OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Orchestra BioMed Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.65+0.20 (+3.67%)
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Orchestra BioMed statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Market Cap | $339.59M | $229.23M |
| Enterprise Value | $229.63M | $194.73M |
| PS Ratio | 10.62 | 3.14 |
Enterprise value
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| EV / Sales | 7.18 | 2.93 |
Income (trailing twelve months)
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Revenue | $31.98M | $102.39M |
| Gross Profit | $31.82M | $60.36M |
| Operating Income | -$57.99M | -$4.31M |
| Net Income | -$59.03M | -$6.57M |
| EBITDA | -$57.64M | -$1.98M |
| EPS (Diluted) | -$1.01 | -$0.07 |
Margins
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Gross Margin | 99.5% | 55.1% |
| Operating Margin | -181.4% | -6.04% |
| Profit Margin | -184.6% | -10.5% |
| EBITDA Margin | -180.3% | -2.67% |
| FCF Margin | -184.8% | -0.30% |
Returns
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Return on Assets (ROA) | -74.5% | -13.3% |
| Return on Capital Employed (ROCE) | -56.7% | -9.07% |
Growth
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 986.1% | 8.85% |
| Revenue Growth (3Y CAGR) | 111.6% | 7.08% |
Balance sheet
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $109.96M | $37.33M |
| Net Cash (Debt) | $109.96M | $3.92M |
| Net Cash Per Share | $1.83 | $0.28 |
| Working Capital | $97.77M | $54.64M |
Financial position
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Current Ratio | 8.26 | 2.50 |
| Quick Ratio | 8.17 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Operating Cash Flow | -$58.32M | -$653.46K |
| Capital Expenditures | -$781.00K | -$3.69M |
| Free Cash Flow | -$59.10M | -$835.02K |
| FCF Per Share | -$0.98 | -$0.02 |
Efficiency
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Asset Turnover | 0.40 | 0.59 |
| Inventory Turnover | 0.72 | 2.21 |
| Revenue Per Employee | $371.81K | $322.75K |
| Profits Per Employee | -$686.38K | -$52.11K |
| Employee Count | 86 | 197 |
Dividends and yields
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Earnings Yield | -17.4% | -6.92% |
| FCF Yield | -17.4% | -0.62% |
Shares
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Shares Outstanding | 60,105,000 | 44,856,700 |
| Shares Change (YoY) | 58.0% | 3.35% |
| Shares Change (QoQ) | 2.51% | 0.27% |
| Float | 26,081,900 | 36,934,400 |
| Shares Held by Insiders | 56.6% | 10.6% |
| Shares Held by Institutions | 46.1% | 63.5% |
Scores
| Measure | Orchestra BioMed | Industry median |
|---|---|---|
| Altman Z-Score | -2.93 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | 7.03 | -2.64 |
Calculated by StockData from Orchestra BioMed's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.